Tumour neoantigen mimicry by microbial species in cancer immunotherapy
|
abstract
|
Tumour neoantigens arising from cancer-specific mutations generate a
molecular fingerprint that has a definite specificity for cancer.
Although this fingerprint perfectly discriminates cancer from
healthy somatic and germline cells, and is therefore therapeutically
exploitable using immune checkpoint blockade, gut and extra-gut
microbial species can independently produce epitopes that resemble
tumour neoantigens as part of their natural gene expression
programmes. Such tumour molecular mimicry is likely not only to
influence the quality and strength of the body's anti-cancer immune
response, but could also explain why certain patients show
favourable long-term responses to immune checkpoint blockade while
others do not benefit at all from this treatment. This article
outlines the requirement for tumour neoantigens in successful cancer
immunotherapy and draws attention to the emerging role of
microbiome-mediated tumour neoantigen mimicry in determining
checkpoint immunotherapy outcome, with far-reaching implications for
the future of cancer immunotherapy.
|
| |
|
|
citation
|
Bösch M, Baty F, Rothschild S I, Tamm M, Joerger M, Früh M,
Brutsche M. Tumour neoantigen mimicry by microbial species in cancer
immunotherapy. Br J Cancer 2021; 125:313-323.
|
| |
|
|
type
|
journal paper/review (English)
|
|
date of publishing
|
06-04-2021
|
|
journal title
|
Br J Cancer (125/3)
|
|
ISSN electronic
|
1532-1827
|
|
pages
|
313-323
|
|
PubMed
|
33824481
|
|
DOI
|
10.1038/s41416-021-01365-2
|
additional links & downloads
